Previous 10 | Next 10 |
-- Survey results of practicing rheumatologists suggest presence of negative gout stigma in causality and management of gout -- -- New analyses of real-world experience of KRYSTEXXA ® (pegloticase injection) adds to the body of data supporting the use of concomitant i...
Horizon Therapeutics reported positive topline results from the MIRROR study of Krystexxa in combination with methotrexate. The results pave the ways for the sBLA submission in Q1 2022, approval should allow the company to aggressively promote the combination which is currently used o...
-- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration in first quarter of 2022 based on significant improvement in response rate -- -- Detailed results to be presented at upcoming medical congress -- ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named to Newsweek’s inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies recognized for employee happiness and satisfaction at work. Out of the companies recognized in the b...
-- Comprehensive OPTIC-X trial results published in Ophthalmology, including new long-term follow-up data -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED. Data were published...
Shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded today at $116.61, eclipsing its 52-week high. Approximately 128,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares. Based on a current price of $114.78, Horizon Therap...
-- Findings presented at ECTRIMS 2021 suggest that deep, persistent B-cell depletion is linked to reduced disease activity -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results from a new analysis of the UPLIZNA pivotal Phase 2/3 N-MOmentum trial indicating a co...
-- Highlights include a poster presentation about real-world adherence to TEPEZZA and an oral presentation sharing data from the OPTIC-X extension trial in people with Thyroid Eye Disease (TED) who have low-level inflammation -- Horizon Therapeutics plc (Nasdaq: HZNP) today ...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and opera...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation for Adoption for the third year in a row. The list, which recognizes organizations with the most robust a...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...